Earlier this month, ACON Investments, a Washington, DC-based international private equity investment firm, announced that affiliates of ACON Latin America Opportunities Fund IV, L.P., in partnership with Humus Capital Partners (HCP), a middle-market private equity firm based in Buenos Aires, have acquired a majority equity interest in Biosidus S.A. and Biosidus Farma S.A. According to the press release, Biosidus is Argentina’s largest manufacturer and distributor of biosimilar pharmaceuticals, with biosimilars for the treatment of chronic renal failure, cancer, multiple sclerosis, growth hormone deficiency and osteoporosis. ACON states that it and HCP “will continue Biosidus’ international expansion strategy, building on its track record of more than 150 million doses of biosimilar pharmaceuticals produced over the last two decades.” The press release quotes Biosidus’ CEO and current shareholder, Santiago García Belmonte, as stating: “I believe that this investment confirms the value our team has built in Biosidus as one of the premier biosimilar pharmaceutical companies in Latin America and the outstanding opportunities presented by biosimilars around the world. We have been searching for the right partners to take our company to the next level and help us capture those opportunities, and I believe that we have found them in ACON and HCP.”
The post Deal Watch: ACON Investments and Humus Capital Acquire Biosidus appeared first on Big Molecule Watch.